Abstract
Welcome to this special JAC-Antimicrobial Resistance Supplement, which is sponsored by Shionogi BV. The march of increasing Gram-negative resistance is relentless, and in the last 10 years we have seen a development in the pipeline of antimicrobials targeting the most resistant Gram-negative bacteria. Within this Supplement, we will present the current landscape for Gram-negative treatments, the launch data for cefiderocol, UK potential positioning and examples of early use. The prescribing information for cefiderocol is available at: https://shionogi-eu-content.com/gb/fetcroja/pi.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
